Cancer

BRAF and MEK inhibitors

Targeted drugs for tumours with a BRAF V600 mutation, about half of melanomas: a BRAF inhibitor combined with a MEK inhibitor blocks the MAPK pathway at two points.

Mechanism of action

Molecular targets

Drugs in BRAF and MEK inhibitors

Therapeutic uses

Diseases it treats

Adverse effects

Contraindications by condition

Other cautions and interactions

Connected topics

Written from

Educational reference. Not medical advice, diagnosis or treatment.